Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers

Biopharmaceutics and Drug Disposition

Volumn 19, Issue 7, 1998, Pages 455-463

  Robbins, Doris K ^a,b   Castles, Mark A ^a   Pack, David J ^a   Bhargava, Vijay O ^a   Weir, Scott J ^a  

^a SANOFI   (France)

^b Hoechst Marion Roussel   (United States)

Author keywords

Achiral; Enantiomers; Fexofenadine hydrochloride; Healthy males; MDL 16455; Pharmacokinetics

Indexed keywords

ANTIHISTAMINIC AGENT; FEXOFENADINE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; ENANTIOMER; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; SPECTROMETRY, FLUORESCENCE; STEREOISOMERISM; TERFENADINE;

EID: 0031695302     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199810)19:7<455::AID-BDD130>3.0.CO;2-W     Document Type: Article

References (18)

1. D.A. Gareitz, R.H. Hook, B.J. Walker and R.A. Okerholm, Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneim. Forsch., 32, 1185-1190 (1982).
2. K. Tasaka, M. Mio and M. Okamoto, Intracellular calcium release induced by histamine releasers and its inhibition by some antiallergic drugs. Ann. Allergy, 56, 464-469 (1986).
3. M. Akagi, M. Mio, K. Miyoshi, J. Smith and K. Tasaka, Antiallergic effects of terfenadine on immediate type hypersensitivity reactions. Immunopharmacol. Immunotoxicol., 9, 257-279 (1987).
4. J.H. Day, M.P. Brisco, A. Welsh and J. Mason, Onset of action, efficacy and safety of a single dose of 60 mg and 120 mg fexofenadine HCl for ragweed (RW) allergy using controlled antigen exposure in an environmental exposure unit (EEU). J. Allergy Clin. Immunol., 97(1 pt 3), Abstract 2007 (1996).
5. F.E.R. Simons, J.N. Bergman, W.T.A. Watson and K.J. Simons, The clinical pharmacology of fexofenadine in children. J. Allergy Clin. Immunol., 98(6 pt 1), 1062-1064 (1996).
6. T.L. Russell, M.L. Stoltz, V.O. Bhargava, M.G. Eller and S. Weir, Acute and subchronic dose tolerance of fexofenadine HCl in healthy male subjects. Ann. Allergy Asthma Immunol., 76, 96 (1996).
7. D. Bernstein, W. Schoenwetter, R. Nathan, W. Storms and J. Mason, Fexofenadine: a new nonsedating antihistamine is effective in the treatment of seasonal allergic rhinitis. J. Allergy Clin. Immunol., 97(1 pt 3), 435 (1996).
8. D. Tinkelman, C. Falliers, E. Bronsky, H. Kaiser and J. Mason, Efficacy and safety of fexofenadine HCl in fall seasonal allergic rhinitis. J. Allergy Clin. Immunol., 97(1 pt 3), 435 (1996).
9. M. Gibaldi and D. Perrier (Eds), Pharmacokinetics, 2nd ed, Marcel Decker, New York, 1982.
10. Food and Drug Administration, Division of Bioequivalence, Office of Generic Drugs, Guidance - Statistical Procedures for Bioequivalence Studies Using a Standard Two Treatment Crossover Design, July 1992.
11. C. Lippert, J. Ling, P. Brown, S. Burmaster, M. Eller, L. Cheng, R. Thompson and S. Weir, Mass balance and pharmacokinetics of MDL 16,455A in healthy male volunteers. Pharm. Res., 12(suppl 9), Abstract PPDM 8253 (1995).
12. S.G. Nerurkar, S.V. Dighe and R.L. Williams, Bioequivalence of racemic drugs. J. Clin. Pharmacol., 32, 935-943 (1992).
13. J. Hendel and H. Brodthagen, Entero-hepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker. Eur. J. Clin. Pharmacol., 26, 103-107 (1984).
14. I. Tamai, H-Y. Ling, S-M. Timbul, J. Nishikido and A. Tsuji, Stereospecific absorption and degradation of cephalexin. J. Pharm. Pharmacol., 40, 320-324 (1988).
15. L. Z. Benet, C-Y. Wu, M.F. Hebert and V.J. Wacher, The importance of drug metabolism and antitransport processes: A paradigm shift in oral drug delivery. J. Contr. Rel., 39, 139-143 (1996).
16. G. Stratmann, A. Jarosch, A. Sulzbacher, R. Schuler, G. Kumel and B.C. Woodcock, Transmembraneous transport of drugs: implications for kinetics and drug action. Int. J. Clin. Pharmacol. Ther., 35, 151-154 (1997).
17. L. Borgstrom, L. Nyberg, S. Jonsson, C. Lindberg and J. Paulson, Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. Br. J. Clin. Pharmacol., 27, 49-56 (1989).
18. J.J. Lima, H. Boudoulas and B.J. Shields, Stereoselective pharmacokinetics of disopyramide enantiomers in man. Drug Metab. Dispos.,13, 572-577 (1985).